Vernalis plc (LON:VER)‘s stock had its “buy” rating restated by stock analysts at Panmure Gordon in a report issued on Thursday. They presently have a GBX 76 ($0.99) price target on the stock. Panmure Gordon’s price target points to a potential upside of 72.24% from the stock’s previous close.
A number of other equities research analysts have also weighed in on the company. Stifel Nicolaus boosted their price target on Vernalis plc from GBX 94 ($1.23) to GBX 99 ($1.29) and gave the stock a “buy” rating in a research note on Tuesday, September 6th. Canaccord Genuity restated a “buy” rating and set a GBX 84 ($1.10) price target on shares of Vernalis plc in a research note on Friday, July 8th. Finally, Shore Capital restated a “house stock” rating on shares of Vernalis plc in a research note on Tuesday, July 19th. Four equities research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus target price of GBX 80.20 ($1.05).
Shares of Vernalis plc (LON:VER) opened at 44.125 on Thursday. The firm’s 50-day moving average is GBX 43.86 and its 200-day moving average is GBX 46.27. Vernalis plc has a one year low of GBX 31.00 and a one year high of GBX 84.75. The stock’s market capitalization is GBX 196.41 million.
Vernalis plc Company Profile
Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine.
Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with MarketBeat.com's FREE daily email newsletter.